Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 522

1.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
2.

The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):276-81. Epub 2007 Dec 11.

PMID:
18063020
3.

Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN.

Gynecol Oncol. 2008 Feb;108(2):336-41. Epub 2007 Nov 19.

PMID:
18006047
4.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126
5.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
6.

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE.

Gynecol Oncol. 2007 Apr;105(1):211-7. Epub 2007 Jan 18.

PMID:
17239941
7.

Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.

Leiser AL, Chi DS, Ishill NM, Tew WP.

Gynecol Oncol. 2007 Jun;105(3):657-61. Epub 2007 Mar 28.

PMID:
17395252
8.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
9.

Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer.

Uyar D, Frasure HE, Markman M, von Gruenigen VE.

Gynecol Oncol. 2005 Sep;98(3):403-8.

PMID:
16000216
10.

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.

Kuhn W, Rutke S, Sp├Ąthe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H.

Cancer. 2001 Nov 15;92(10):2585-91.

PMID:
11745193
11.

The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma.

Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC.

BJOG. 2009 Feb;116(3):372-80. doi: 10.1111/j.1471-0528.2008.02033.x.

12.

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA.

Gynecol Oncol. 2005 May;97(2):436-41.

PMID:
15863142
13.

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR.

Gynecol Oncol. 2009 Jul;114(1):26-31. doi: 10.1016/j.ygyno.2009.03.018. Epub 2009 Apr 23.

PMID:
19395008
14.

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA.

J Reprod Med. 2005 Jun;50(6):426-38. Review.

PMID:
16050567
15.

Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.

Eichbaum MH, Weiss LM, Bruckner T, Schneeweiss A, Sinn HP, Gebauer G, Fersis N, Kussmaul J, Sohn C.

Med Sci Monit. 2009 Apr;15(4):CR156-63.

PMID:
19333199
16.

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.

Gynecol Oncol. 2006 Aug;102(2):285-91. Epub 2006 Mar 3.

PMID:
16516283
17.

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.

Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.

Gynecol Oncol. 2009 Aug;114(2):253-9. doi: 10.1016/j.ygyno.2009.04.024. Epub 2009 May 14.

PMID:
19446316
18.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):83-9. Epub 2007 Nov 19.

PMID:
18025437
19.

Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.

Estes JM, Leath CA 3rd, Straughn JM Jr, Rocconi RP, Kirby TO, Huh WK, Barnes MN 3rd.

J Am Coll Surg. 2006 Oct;203(4):527-32. Epub 2006 Aug 17.

PMID:
17000397
20.

Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.

Karam AK, Chiang JW, Fung E, Nossov V, Karlan BY.

Gynecol Oncol. 2009 Aug;114(2):246-52. doi: 10.1016/j.ygyno.2009.02.022. Epub 2009 Jun 4.

PMID:
19500821

Supplemental Content

Support Center